Abstract:Immune checkpoint blockade (ICB) immunotherapy strategies have yielded significant successes in recent years. Unfortunately, such treatments are not always successful. While tumor resistance to immunotherapy is often the reason, a subpopulation of patients treated with ICB show an acceleration in tumor growth rate, termed hyperprogressive disease (HPD) or hyperprogression (HP). Different studies have evaluated the incidence rate of HPD at 4% to 30%, though clear predictors have been elusive. An impediment to progress on investigating HPD has long been the lack of a reliable disease model. We recently reported a humanized mouse model of hyperprogression using mismatch repair deficient (MMR-d) p53-/- HCT-116 colorectal cancer cells implanted subcutaneously into athymic mice humanized with human CD8+ T-cell line TALL-104 and treated with anti-PD-1 Pembrolizumab. Flow cytometry was used to ensure the systemic establishment of the TALL-104 CD8+ human T-cells used to humanize the athymic mice and characterize immune tumor infiltration, which was not different between groups. Immunoperoxidase staining revealed increased expression of proliferation marker Ki67 within the HPD xenografts, supporting the finding that HPD tumors were exhibiting accelerated growth. Initial human cytokine analysis revealed a significant elevation in three cytokines (IFN-γ, TRAIL R2, and RANK L) and a significant decrease in four (CCL2, Chitinase 3-like 1, IL-4, and TNF-α). We attempted to mitigate HP through administration of anti-EGFR Panitumumab based on some clinical studies linking EGFR aberration to HPD but found worsened HPD in cotreated mice. We are conducting RNA sequencing to identify any changes in the RNAome of the HPD model, and immunoperoxidase analysis of resected tumor tissue for cytokine expression and cell death markers that may provide clues for accelerated growth within the HPD tumor microenvironment. Future studies will also focus on the interplay between Pembrolizumab and Panitumumab observed preliminarily to exacerbate the HPD with more comprehensive in vivo studies including of patient-derived xenotransplants. Citation Format: Andrew George, Ilyas Sahin, Shengliang Zhang, Wafik S. El-Deiry. Role of the cancer cell proteome and tumor microenvironment in the hyperprogression (HP) phenotype response to immune checkpoint blockade [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3548.

Hyperprogression under Treatment with Immune-Checkpoint Inhibitors in Patients with Gastrointestinal Cancer: A Natural Process of Advanced Tumor Progression?

Hyperprogression after Immunotherapy in Patients with Malignant Tumors of Digestive System

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

Hyperprogressive disease in patients receiving immune checkpoint inhibitors

Hyperprogression: A Novel Response Pattern under Immunotherapy.

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.

Pseudoprogression and Hyperprogression after Checkpoint Blockade

Intersection of Immune and Oncometabolic Pathways Drives Cancer Hyperprogression During Immunotherapy.

Abstract 3548: Role of the cancer cell proteome and tumor microenvironment in the hyperprogression (HP) phenotype response to immune checkpoint blockade

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

Hyperprogressive Disease in Cervical Small Cell Carcinoma Treated by Immune Checkpoint Inhibitor

Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy

Hyperprogressive Disease During PD-1 Blockade in Patients with Advanced Pancreatic Cancer